RegenXBio's market cap is currently ―. The company's EPS TTM is $-5.877; its P/E ratio is -2.68; RegenXBio is scheduled to report earnings on August 7, 2024, and the estimated EPS forecast is $-1.29. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 22.21M	$ 28.91M	$ 19.98M	$ 19.14M	$ 31.34M
Gross Profit	$ 10.97M	$ 16.53M	$ 10.53M	$ 14.99M	$ 25.94M
EBIT	$ -61.68M	$ -60.24M	$ -70.94M	$ -66.16M	$ -57.77M
EBITDA	$ -57.60M	$ -56.01M	$ -66.13M	$ -61.30M	$ -70.67M
Net Income Common Stockholders	$ -62.89M	$ -61.43M	$ -72.06M	$ -66.68M	$ -59.94M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 275.26M	$ 301.89M	$ 320.08M	$ 331.82M	$ 364.64M
Total Assets	$ 573.97M	$ 633.79M	$ 682.46M	$ 747.83M	$ 691.58M
Total Debt	$ 89.29M	$ 90.70M	$ 91.58M	$ 93.30M	$ 94.80M
Net Debt	$ -185.97M	$ -211.19M	$ -228.50M	$ -238.52M	$ -269.84M
Total Liabilities	$ 262.23M	$ 270.69M	$ 276.60M	$ 282.69M	$ 833.22M
Stockholders Equity	$ 311.74M	$ 363.10M	$ 405.85M	$ 465.14M	$ 516.15M
Cash Flow	-
Free Cash Flow	$ -41.89M	$ -50.85M	$ -49.90M	$ -85.74M	$ -44.85M
Operating Cash Flow	$ -40.76M	$ -49.41M	$ -47.32M	$ -80.92M	$ -39.38M
Investing Cash Flow	$ 33.97M	$ 38.66M	$ 55.22M	$ 63.09M	$ 26.70M
Financing Cash Flow	$ -11.96M	$ -4.80M	$ -9.16M	$ -9.04M	$ -8.92M

Currency in USD

RegenXBio Earnings and Revenue History

Income Statement >

RegenXBio Debt to Assets

Balance Sheet >

RegenXBio Cash Flow

Cash Flow >

RegenXBio Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing